Author: Kevin Grogan

GlaxoSmithKline’s Avandia is once again making the headlines after it was revealed that the peer reviewer looking at the now-notorious meta-analysis on the diabetes drug’s safety profile leaked a confidential copy of the article to the firm before it was published in the New England Journal of Medicine.

The fall-out from the Vytorin data published by Merck & Co and Schering-Plough has again hurt the share price of the two firms but the cholesterol drug has received support from the American College of Cardiology.

Belgium’s UCB and Teva Pharmaceutical Industries have entered into a pact which will see the two companies jointly commercialise the Israeli-headquartered firm’s respiratory medicines in the USA.

Charities and scientists have hailed a new study from US researchers which appears to have dramatically expanded the list of potential drug targets to treat AIDS.

GlaxoSmithKline has again spoken out in defence of Seroxat as reports re-emerged concerning lawsuits being filed in the UK against the firm and its blockbuster antidepressant.